Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints - PubMed (original) (raw)
Review
Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints
Hong Jiang et al. Curr Opin Virol. 2015 Aug.
Abstract
Oncolytic adenoviruses are modified to exploit the aberrant expression of proteins in cancer cells to obtain cancer-selective replication. Moreover, the natural tropism of oncolytic adenoviruses can be redirected to tumor cells. Clinical trials revealed that oncolytic viruses showed poor replication in the tumor that is due in part to the immune response against the virus. More recent data demonstrated that tumor infection might subvert the tumor immune system and lead to an anti-tumor immune response. In the next few years, combination of adenoviruses with immune checkpoint antibodies and other immune modulators will be tested in clinical trials.
Copyright © 2015 Elsevier B.V. All rights reserved.
Figures
Figure 1. Dual mechanism of cancer virotherapy
Viral-mediated anticancer effect in vivo would depend on success of the two stages: viral replication with the effect of viral-induced oncolysis and the subsequent immune response. The first stage, viral-induced oncolysis, should probably be 1) enhanced by directing the tropism of the adenovirus to cancer cells, per instance with the insertion of an RGD-motif peptide sequence in the viral fiber knob; 2) restricted to cancer cells, and this can be achieved by modifying the viral proteins that interact with cellular proteins, per instance, via mutations of the early viral proteins E1A or E1B; and 3) modified by accelerating the lysis process, per instance by increasing autophagy with autophagy regulators. The anti-virus and anti-tumor immune responses are elicited by the accumulation of pathogen-associated molecular patterns (PAMPs), which reflect conserved components of microbes and viruses, per instance the adenovirus capsid proteins, together with the release to the tumor milieu of danger-associated molecular patterns (DAMPs), which are responsible for the attraction of innate immune cells and eventually for T cell priming. It is possible that tumor regression after adenoviral infection would exclusively occur if the anti-tumor immune response is elicited and maintained.
Figure 2. Rationale for the combination of oncolytic adenoviruses with immune checkpoint modulators
Future personalized medicine in the field of oncolytic virotherapy might depend on the degree of tumor immunogenicity, the status of the host immune response with respect to tumor cells, and the levels of expression of immune checkpoints and other positive and negative regulators of anergy. Combination therapy might be required particularly for patients with weak Th1 primed lymphocytes, and high levels of expression of immune checkpoints in the tumor infiltrative T cells, and with a low degree of immunogenicity. Further preclinical studies would be necessary to buttress these algorithms.
Similar articles
- Going viral: a review of replication-selective oncolytic adenoviruses.
Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Larson C, et al. Oncotarget. 2015 Aug 21;6(24):19976-89. doi: 10.18632/oncotarget.5116. Oncotarget. 2015. PMID: 26280277 Free PMC article. Review. - Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D. Liu TC, et al. Gene Ther. 2005 Sep;12(17):1333-46. doi: 10.1038/sj.gt.3302555. Gene Ther. 2005. PMID: 15920462 - Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A, Suzuki M. Rosewell Shaw A, et al. Curr Opin Virol. 2016 Dec;21:9-15. doi: 10.1016/j.coviro.2016.06.009. Epub 2016 Jul 2. Curr Opin Virol. 2016. PMID: 27379906 Free PMC article. Review. - Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C, Fueyo J. Gomez-Manzano C, et al. Curr Opin Mol Ther. 2010 Oct;12(5):530-7. Curr Opin Mol Ther. 2010. PMID: 20886384 Review. - [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA, Tarasova MV, Netesov SV, Chumakov PM. Sviatchenko VA, et al. Mol Biol (Mosk). 2012 Jul-Aug;46(4):556-69. Mol Biol (Mosk). 2012. PMID: 23113343 Review. Russian.
Cited by
- Oncolytic Activity of Sindbis Virus with the Help of GM-CSF in Hepatocellular Carcinoma.
Shi X, Sun K, Li L, Xian J, Wang P, Jia F, Xu F. Shi X, et al. Int J Mol Sci. 2024 Jun 29;25(13):7195. doi: 10.3390/ijms25137195. Int J Mol Sci. 2024. PMID: 39000311 Free PMC article. - Endovascular Applications for the Management of High-Grade Gliomas in the Modern Era.
Kappel AD, Jha R, Guggilapu S, Smith WJ, Feroze AH, Dmytriw AA, Vicenty-Padilla J, Alcedo Guardia RE, Gessler FA, Patel NJ, Du R, See AP, Peruzzi PP, Aziz-Sultan MA, Bernstock JD. Kappel AD, et al. Cancers (Basel). 2024 Apr 22;16(8):1594. doi: 10.3390/cancers16081594. Cancers (Basel). 2024. PMID: 38672676 Free PMC article. Review. - Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas.
Meléndez-Vázquez NM, Nguyen TT, Fan X, López-Rivas AR, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Meléndez-Vázquez NM, et al. Mol Ther Oncol. 2024 Feb 28;32(1):200787. doi: 10.1016/j.omton.2024.200787. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596290 Free PMC article. - Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma.
Hu M, Liao X, Tao Y, Chen Y. Hu M, et al. Front Immunol. 2023 Nov 2;14:1285113. doi: 10.3389/fimmu.2023.1285113. eCollection 2023. Front Immunol. 2023. PMID: 38022620 Free PMC article. Review. - Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, He J, Gillard AG, Lang FF, Gomez-Manzano C, Fueyo J. Jiang H, et al. Cancer Res Commun. 2023 Jun 27;3(6):1118-1131. doi: 10.1158/2767-9764.CRC-23-0054. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37379361 Free PMC article.
References
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
- Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther. 2006;6:697–708. - PubMed
- Jiang H, McCormick F, Gomez-Manzano C, Curiel DT, Lang FF, Yung WKA, Fueyo J. In: Replicating viruses for brain tumor treatment. Castro M, Lowenstein P, editors. Taylor & Francis; New York: 2006.
- Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9:64–71. - PubMed
- Alemany R. Chapter four--Design of improved oncolytic adenoviruses. Adv Cancer Res. 2012;115:93–114. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources